Polymorphonuclear granulocytes induce antibody-dependent apoptosis in human breast cancer cells

被引:55
作者
Stockmeyer, B
Beyer, T
Neuhuber, W
Repp, R
Kalden, JR
Valerius, T
Herrmann, M
机构
[1] Univ Erlangen Nurnberg, Dept Internal Med 3, D-91054 Erlangen, Germany
[2] Univ Erlangen Nurnberg, Dept Anat 1, D-91054 Erlangen, Germany
关键词
D O I
10.4049/jimmunol.171.10.5124
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Recent studies in HER-2/neu-targeted immunotherapy demonstrated that polymorphonuclear neutrophils (PMN) mediated Ab-dependent cellular cytotoxicity against HER-2/neu-positive breast cancer cell lines. However, the mechanism of cell death remained unclear. We used several assays to analyze the induction of apoptosis in the breast cancer cell line SK-BR-3 via PMN-dependent Ab-dependent cellular cytotoxicity. In the presence of the HER-2/neu Ab 520C9 and PMN from healthy donors, apoptosis occurred as detected by annexin V binding and disappearance of euploid SK-BR-3 nuclei, which can be differentiated from PMN nuclei by their increased DNA contents. Apoptosis induction was observed with E:T cell ratios as low as 10:1. Laser scanning fluorescence microscopy of TUNEL tumor cells or staining for cleaved cytokeratin-18 further confirmed apoptosis of the SK-BR-3 breast cancer cells. Killing via 520C9 was dependent on the interaction with FcR on PMN, because 1) F(ab')(2) fragments of 520C9 mediated no cytotoxicity, 2) target cell death was influenced by a biallelic polymorphism of FcgammaRIIa on the effector cells, and 3) a bispecific Ab against HER-2/neu and the IgA receptor (FcalphaRI) expressed on effector cells significantly induced apoptosis. Thus, PMN induce Ab-dependent apoptosis against human breast cancer cells targeted with HER-2/neu-directed mAbs or FcR directed bispecific Abs.
引用
收藏
页码:5124 / 5129
页数:6
相关论文
共 45 条
[31]  
REPP R, 2000, P ASCO, V19, pA475
[32]  
RING DB, 1989, CANCER RES, V49, P3070
[33]   Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. [J].
Slamon, DJ ;
Leyland-Jones, B ;
Shak, S ;
Fuchs, H ;
Paton, V ;
Bajamonde, A ;
Fleming, T ;
Eiermann, W ;
Wolter, J ;
Pegram, M ;
Baselga, J ;
Norton, L .
NEW ENGLAND JOURNAL OF MEDICINE, 2001, 344 (11) :783-792
[34]   HUMAN-BREAST CANCER - CORRELATION OF RELAPSE AND SURVIVAL WITH AMPLIFICATION OF THE HER-2 NEU ONCOGENE [J].
SLAMON, DJ ;
CLARK, GM ;
WONG, SG ;
LEVIN, WJ ;
ULLRICH, A ;
MCGUIRE, WL .
SCIENCE, 1987, 235 (4785) :177-182
[35]   Epidermal growth factor receptor and G250:: Useful target antigens for antibody mediated cellular cytotoxicity against renal cell carcinoma? [J].
Stadick, H ;
Stockmeyer, B ;
Kühn, R ;
Schrott, KM ;
Kalden, JR ;
Glennie, MJ ;
Van De Winkel, JGJ ;
Gramatzki, M ;
Valerius, T ;
Elsässer, D .
JOURNAL OF UROLOGY, 2002, 167 (02) :707-712
[36]   Triggering FCα-receptor I (CD89) recruits neutrophils as effector cells for CD20-directed antibody therapy [J].
Stockmeyer, B ;
Dechant, M ;
van Egmond, M ;
Tutt, AL ;
Sundarapandiyan, K ;
Graziano, RF ;
Repp, R ;
Kalden, JR ;
Gramatzki, M ;
Glennie, MJ ;
van de Winkel, JGJ ;
Valerius, T .
JOURNAL OF IMMUNOLOGY, 2000, 165 (10) :5954-5961
[37]  
Stockmeyer B, 1997, CANCER RES, V57, P696
[38]   Mechanisms of G-CSF- or GM-CSF-stimulated tumor cell killing by Fc receptor-directed bispecific antibodies [J].
Stockmeyer, B ;
Elsässer, D ;
Dechant, M ;
Repp, R ;
Gramatzki, M ;
Glennie, MJ ;
van de Winkel, JGJ ;
Valerius, T .
JOURNAL OF IMMUNOLOGICAL METHODS, 2001, 248 (1-2) :103-111
[39]   Fc alpha RI (CD89) as a novel trigger molecule for bispecific antibody therapy [J].
Valerius, T ;
Stockmeyer, B ;
vanSpriel, AB ;
Graziano, RF ;
vandenHerikOudijk, IE ;
Repp, R ;
Deo, YM ;
Lund, J ;
Kalden, JR ;
Gramatzki, M ;
vandeWinkel, JGJ .
BLOOD, 1997, 90 (11) :4485-4492
[40]   IgG receptor polymorphisms: risk factors for disease [J].
van der Pol, WL ;
van de Winkel, JGJ .
IMMUNOGENETICS, 1998, 48 (03) :222-232